Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Liver gene expression analysis of male ApoE-/- mice treated with Isoginkgetin

ABSTRACT: Liver gene expression analysis of male ApoE-/- mice treated with Isoginkgetin

PROVIDER: PRJNA1089219 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28380436_1.fastq.gz	Fastqsanger.gz
	SRR28380436_2.fastq.gz	Fastqsanger.gz
	SRR28380437_1.fastq.gz	Fastqsanger.gz
	SRR28380437_2.fastq.gz	Fastqsanger.gz
	SRR28380438_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Liver gene expression analysis of male ApoE-/- mice treated with Isoginkgetin

Project description:Isoginkgetin (ISOGK) is a biflavone derived from Ginkgo Biloba that inhibits RNA splicing. ISOGK has been reported to have various protective effects, including anti-inflammatory, antioxidant, and anti-tumorigenic properties. The study aimed to investigate the impact of ISOGK treatment on atherosclerosis induced by a Western diet in ApoE-/- mice. After seven weeks of a high-fat diet, ISOGK was administered intraperitoneally for eight weeks. At the endpoint, mice were euthanized for sample collection, and a series of indicators were tested. The study results indicate that the ISOGK treatment group significantly reduced the area of aortic plaques, aortic sinus plaques, and the necrotic core area. Additionally, ISOGK significantly lowered the levels of total cholesterol in the serum. These findings suggest that ISOGK is effective in treating atherosclerosis and reducing blood lipid levels.

2024-05-15 | GSE261858 | GEO

ApoE-knockout mice liver on high fat diet treated with trehalose or agmatine.

Project description:ApoE-knockout mice liver on high fat diet developing liver steatosis were treated with trehalose or agmatine for 16 weeks.

2024-08-10 | PXD049421 | Pride

Proteomic analysis of liver cytosol and mitochondria of apoE-KO mice treated with TUG-891.

Project description:ApoE-KO mice were treated with FFAR4 agonist TUG-891 for 16 weeks. Protein abundance changes in relation to untreated control were measured in liver samples fractionated to cytosol and mitochondria by SWATH-MS.

2024-08-09 | PXD028535 | Pride

Microarray analysis of isoginkgetin-treated HCT116 and HCT116p53-/- cells

Project description:Microarray analysis of isoginkgetin-treated HCT116 and HCT116p53-/- cells

| PRJNA748989 | ENA

Proteomic analysis of apoE-KO mice liver exposed to inhaled silicon dioxide.

Project description:ApoE-KO mice were treated with silicon monoxide for 16 weeks. Protein abundance changes in relation to untreated control were measured in liver samples fractionated to cytosol and mitochondria by SWATH-MS.

2023-03-11 | PXD028547 | Pride

Isoginkgetin induces autophagic cell death in hepatocellular carcinoma [RNA-Seq]

Project description:Purpose: Our previous studies have identified Isoginkgetin as an inducer of autophagic cell death in hepatocellular carcinoma. We set out to analyze how isoginkgetin regulates gene expression in HepG2 cells. Methods: RNA-seq was performed with two repetitions in HepG2 followed by treatment with DMSO and 20 μM Isoginkgetin for 24 h. Conclusions: Isoginkgetin treatment reduces the expression of glucose transporters in HepG2 cells.

2023-03-22 | GSE188533 | GEO

Isoginkgetin induces autophagic cell death in hepatocellular carcinoma [ChIP-Seq]

Project description:Purpose: Our previous studies have identified isoginkgetin as an inducer of autophagic cell death in hepatocellular carcinoma. We set out to analyze how isoginkgetin regulates the genome-wide enhancer activity in HepG2 cells. Methods: ChIP-seq for H3K27ac was performed in HepG2 followed by treatment with 20 μM isoginkgetin for 24 h. Conclusions: Isoginkgetin treatment reduces the expression of glucose transporters and inhibts SLC2A1 enhancer activity in HepG2 cells.

2023-03-22 | GSE188534 | GEO

Isoginkgetin induces autophagic cell death in hepatocellular carcinoma [ChIP-seq 2]

Project description:Purpose: Our previous studies have identified isoginkgetin as an inducer of autophagic cell death in hepatocellular carcinoma. We set out to analyze how isoginkgetin regulates the genome-wide enhancer activity in HepG2 cells. Methods: ChIP-seqs for H3K4me, H4K8ac, H3K27me3 and H3K9ac were performed in HepG2 followed by treatment with 20 μM isoginkgetin for 24 h. Conclusions: Isoginkgetin treatment reduces the expression of glucose transporters and inhibts SLC2A1 enhancer activity in HepG2 cells.

2023-03-22 | GSE202612 | GEO

Hepatic transcriptomics of squalene in male Apoe-deficient mice on Western diet

Project description:Background and Purpose: Squalene is the main hydrocarbon present in extra virgin olive oil and it has been reported to have anti-steatotic properties in different animal models. The aims of this study were to investigate its effects on liver transcriptomics in Male C57BL/6J Apoe-deficient mice. Experimental Approaches: Male C57BL/6J Apoe-deficient mice were fed a purified Western diet with or without squalene during 11 weeks and hepatic squalene content was assessed. Hepatic transcriptomic changes were studied and confirmed by RT-qPCR. Key Results: Squalene supplementation increased its hepatic content. The Cyp2b10 and Cyp2c55 gene expressions were significantly up-regulated by the squalene intake in all animal models, with independence of sex, sexual hormones, dietary fat content, genetic background and dose, and were strongly associated with antioxidant defense capacity and with lipid content and composition. Conclusions and Implications: hepatic squalene exerts its activity through overexpression of these cytochromes and their changes in virgin olive oil diets may be due to squalene.

2021-04-30 | GSE145343 | GEO

Genome-wide analysis of SAK-HV treatment caused hepatic genes expression in ApoE knockout mice

Project description:A novel recombinant fusion protein (SAK-HV) significantly decreased the serum levels of both total cholesterol (TC) and triglyceride (TG) in apolipoprotein E-deficient (ApoE-/-) mice with hyperlipemia and remarkably ameliorated hepatic steatosis. Particularly, its lipid-lowering effect was significantly better than that of atorvastatin during the observation period of 2 weeks. We then collected the liver tissues of SAK-HV-treated ApoE-/- mice (n=7) and liver tissues of PBS-treated ApoE-/- mice to make the transcriptome chip, and analyze the lipid-lowering mechanism of SAK-HV in liver of ApoE-/- mice.

2017-06-13 | GSE88964 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data